New insider activity at ProKidney ( (PROK) ) has taken place on April 15, 2025.
Carso De-C Inmobiliaria has made a significant investment in ProKidney by purchasing 1,034,118 shares of its stock. This transaction is valued at $620,470, highlighting a strong interest and confidence in ProKidney’s potential.
Recent Updates on PROK stock
ProKidney has reported significant developments, including a FY24 revenue of $76,000 compared to $0 last year, marking a pivotal year with progress in clinical, regulatory, manufacturing, and financial initiatives. The company has refined its Phase 3 program to focus on advanced CKD patients, engaged with the FDA to accelerate rilparencel’s market path, improved its manufacturing process, and secured $140 million in equity funding. Looking forward, 2025 is expected to be critical with the release of full Group 1 data from the Phase 2 REGEN-007 study and an update on the accelerated approval pathway for the Phase 3 PROACT 1 study. ProKidney aims to expedite rilparencel’s market entry in the U.S. for advanced CKD and diabetes patients. Additionally, the company’s cash and securities as of December 31, 2024, totaled $358.3 million, expected to fund operations into mid-2027.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney (PROK) faces significant financial challenges, with persistent losses, high operational costs, and negative cash flow. The technical analysis indicates a bearish trend with weak momentum. Valuation metrics highlight substantial unprofitability and lack of dividend appeal. These factors contribute to a low overall stock score, reflecting considerable risk for potential investors.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
YTD Price Performance: -57.75%
Average Trading Volume: 567,237
Technical Sentiment Signal: Buy
Current Market Cap: $214M